Dysregulated expression of secretogranin III is involved in neurotoxin-induced dopaminergic neuron apoptosis

Journal of Neuroscience Research

Volumn 90, Issue 12, 2012, Pages 2237-2246

  Li, Fengrui ^a,b   Tian, Xiaofei ^a   Zhou, Yishu ^a   Zhu, Lanhui ^a   Wang, Baojie ^a   Ding, Mei ^a   Pang, Hao ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b BAOTOU MEDICAL COLLEGE   (China)

Author keywords

Apoptosis; Caspase; Paraquat; Parkinson's disease; Secretogranin III

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE INHIBITOR; DOPAMINE; MESSENGER RNA; NEUROTOXIN; NEUROTRANSMITTER; PARAQUAT; SECRETOGRANIN II; SECRETOGRANIN III; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL COMMUNICATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROBLASTOMA CELL; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

AMINO ACID CHLOROMETHYL KETONES; APOPTOSIS; CASPASE 3; CASPASE 7; CASPASE INHIBITORS; CELL LINE, TUMOR; CHROMOGRANINS; DOPAMINE; DOPAMINERGIC NEURONS; DOWN-REGULATION; HEK293 CELLS; HUMANS; NERVE TISSUE PROTEINS; NEUROBLASTOMA; NEUROTOXINS; OXIDOPAMINE; PARAQUAT; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SUBSTRATE SPECIFICITY;

EID: 84867704444     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23121     Document Type: Article

References (37)

1. Bartolomucci A, Pasinetti GM, Salton SR. 2010. Granins as disease-biomarkers: translational potential for psychiatric and neurological disorders. Neuroscience 170: 289-297.
2. Blake CA, Brown LM, Duncan MW, Hunsucker SW, Helmke SM. 2005. Estrogen regulation of the rat anterior pituitary gland proteome. Exp Biol Med 230: 800-807.
3. Cappelletti G, Maggioni MG, Maci R. 1998. Apoptosis in human lung epithelial cells: triggering by paraquat and modulation by antioxidants. Cell Biol Int 22: 671-678.
4. +, oxidant and specific neurotoxicants shares the common molecular mechanism. J Neurochem 76: 1010-1021.
5. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, Cahill DJ, Emili A, Fitzgerald DJ, Maguire PB. 2004. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 103: 2096-2104.
6. De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. 2000. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology 54: S21-S23.
7. Dowling P, Shields W, Rani S, Meleady P, Henry M, Jeppesen P, O'Driscoll L, Clynes M. 2008. Proteomic analysis of conditioned media from glucose responsive and glucose non-responsive phenotypes reveals a panel of secreted proteins associated with beta cell dysfunction. Electrophoresis 29: 4141-4149.
8. Eder U, Leitner B, Kirchmair R, Pohl P, Jobst KA, Smith AD, Málly J, Benzer A, Riederer P, Reichmann H, Saria A, Winkler H. 1998. Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases. J Neural Transm 105: 39-51.
9. Fei Q, McCormack AL, Di Monte DA, Ethell DW. 2008. Paraquat neurotoxicity is mediated by a Bak-dependent mechanism. J Biol Chem 283: 3357-3364.
10. Gilgun-Sherki Y, Hellmann M, Melamed E, Offen D. 2004. The role of neurotransmitters and neuropeptides in Parkinson's disease: implications for therapy. Drugs Future 29: 1261.
11. González-Polo RA, Rodríguez-Martín A, Morán JM, Niso M, Soler G, Fuentes JM. 2004. Paraquat-induced apoptotic cell death in cerebellar granule cells. Brain Res 1011: 170-176.
12. Han L, Suda M, Tsuzuki K, Wang R, Ohe Y, Hirai H, Watanabe T, Takeuchi T, Hosaka M. 2008. A large form of secretogranin III functions as a sorting receptor for chromogranin A aggregates in PC12 cells. Mol Endocrinol 22: 1935-1949.
13. He C, Huang R, Du F, Zheng F, Wei L, Wu J. 2009. LDL oxidation by THP-1 monocytes: implication of HNP-1, SgIII and DMT-1. Clin Chim Acta 402: 102-106.
14. Hosaka M, Watanabe T. 2010. Secretogranin III: a bridge between core hormone aggregates and the secretory granule membrane. Endocr J 57: 275-286.
15. Hosaka M, Watanabe T, Sakai Y, Uchiyama Y, Takeuchi T. 2002. Identification of a chromogranin A domain that mediates binding to secretogranin III and targeting to secretory granules in pituitary cells and pancreatic beta-cells. Mol Biol Cell 13: 3388-3399.
16. Hosaka M, Suda M, Sakai Y, Izumi T, Watanabe T, Takeuchi T. 2004. Secretogranin III binds to cholesterol in the secretory granule membrane as an adapter for chromogranin A. J Biol Chem 279: 3627-3634.
17. Hosaka M, Watanabe T, Sakai Y, Kato T, Takeuchi T. 2005. Interaction between secretogranin III and carboxypeptidase E facilitates prohormone sorting within secretory granules. J Cell Sci 118: 4785-4795.
18. Hotta K, Hosaka M, Tanabe A, Takeuchi T. 2009. Secretogranin II binds to secretogranin III and forms secretory granules with orexin, neuropeptide Y, and POMC. J Endocrinol 202: 111-121.
19. Jana S, Sinha M, Chanda D, Roy T, Banerjee K, Munshi S, Patro BS, Chakrabarti S. 2011. Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: implications in dopamine cytotoxicity and pathogenesis of Parkinson's disease. Biochim Biophys Acta 1812: 663-673.
20. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schröder FH, van Steenbrugge GJ. 2000. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 60: 741-748.
21. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schröder FH, van Steenbrugge GJ. 2002. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate 50: 203-215.
22. Junn E, Mouradian MM. 2001. Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activatedprotein kinase, cytochrome c and caspases. J Neurochem 78: 374-383.
23. Martyniuk CJ, Xiong H, Crump K, Chiu S, Sardana R, Nadler A, Gerrie ER, Xia X, Trudeau VL. 2006. Gene expression profiling in the neuroendocrine brain of male goldfish (Carassius auratus) exposed to 17alpha-ethinylestradiol. Physiol Genomics 27: 328-336.
24. Moran JM, Gonzalez-Polo RA, Ortiz-Ortiz MA, Niso-Santano M, Soler G, Fuentes JM. 2008. Identification of genes associated with paraquat-induced toxicity in SH-SY5Y cells by PCR array focused on apoptotic pathways. J Toxicol Environ Health A 71: 1457-1467.
25. Moss AC, Jacobson GM, Walker LE, Blake NW, Marshall E, Coulson JM. 2009. SCG3 transcript in peripheral blood is a prognostic biomarker for REST-deficient small cell lung cancer. Clin Cancer Res 15: 274-283.
26. Nilsson A, Fälth M, Zhang X, Kultima K, Sköld K, Svenningsson P, Andrén PE. 2009. Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease. Mol Cell Proteomics 8: 1094-1104.
27. Niso-Santano M, Morán JM, García-Rubio L, Gómez-Martín A, González-Polo RA, Soler G, Fuentes JM. 2006. Low concentrations of paraquat induces early activation of extracellular signal-regulated kinase 1/2, protein kinase B, and c-Jun N-terminal kinase 1/2 pathways: role of c-Jun N-terminal kinase in paraquat-induced cell death. Toxicol Sci 92: 507-515.
28. Palozza P, Simone R, Catalano A, Parrone N, Monego G, Ranelletti FO. 2011. Lycopene regulation of cholesterol synthesis and efflux in human macrophages. J Nutr Biochem 22: 971-978.
29. Pop C, Salvesen GS. 2009. Human caspases: activation, specificity, and regulation. J Biol Chem 284: 21777-21781.
30. Portela-Gomes GM, Grimelius L, Stridsberg M. 2010. Secretogranin III in human neuroendocrine tumours: a comparative immunohistochemical study with chromogranins A and B and secretogranin II. Regul Pept 165: 30-35.
31. Prasad P, Yanagihara AA, Small-Howard AL, Turner H, Stokes AJ. 2008. Secretogranin III directs secretory vesicle biogenesis in mast cells in a manner dependent upon interaction with chromogranin A. J Immunol 181: 5024-5034.
32. Sakai Y, Hosaka M, Yoshinaga A, Hira Y, Harumi T, Watanabe T. 2004. Immunocytochemical localization of secretogranin III in the endocrine pancreas of male rats. Arch Histol Cytol 67: 57-64.
33. Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, Andersen SL, Stephens RM, Benes FM, Sonntag KC. 2009. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 132: 1795-1809.
34. Stridsberg M, Grimelius L, Portela-Gomes GM. 2008. Immunohistochemical staining of human islet cells with region-specific antibodies against secretogranins II and III. J Anat 212: 229-234.
35. Timmer JC, Salvesen GS. 2007. Caspase substrates. Cell Death Differ 14: 66-72.
36. Wichmann T, DeLong MR. 2003. Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann N Y Acad Sci 991: 199-213.
37. Yang W, Tiffany-Castiglioni E. 2008. Paraquat-induced apoptosis in human neuroblastoma SH-SY5Y cells: involvement of p53 and mitochondria. J Toxicol Environ Health A 71: 289-299.